v3.25.0.1
Shareholders' Equity (Tables)
 12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
Schedule of the Stock Option and RSU Award Activities
The following table summarizes the stock option and RSU award activities under the Company's share-based compensation plans for the years ended December 31, 2024 and 2023:
Shares Subject to Options OutstandingOutstanding RSUs
Number of Options(1)
Weighted Average Exercise PriceRemaining Contractual Term (in years)
Aggregate Intrinsic Value(2)
Weighted Average Grant Date Fair ValueOutstanding RSUsWeighted Average Grant Date Fair Value
(in US $ millions, except share and share price amounts)
December 31, 202214,008,761 36.556.71195 — 10,218,906 43.74 
Stock options granted3,133,704 57.89— — 30.08 — — 
Stock options exercised(3,915,216)15.04— — — — — 
Stock options forfeited(1,764,618)35.57— — — — — 
RSUs granted— —— — — 5,262,115 57.84 
RSUs settled— —— — — (7,288,043)45.64 
RSUs forfeited— —— — — (4,114,500)43.79 
December 31, 202311,462,631 49.887.09406 — 4,078,478 58.50 
Stock options granted6,065,237 75.75 — — 39.74 — — 
Stock options exercised(2,576,628)23.83 — — — — — 
Stock options forfeited(314,248)82.40 — — — — — 
RSUs granted— — — — — 7,025,895 74.91 
RSUs settled— — — — — (5,433,218)63.95 
RSUs forfeited— — — — — (550,086)61.51 
December 31, 202414,636,992 64.497.68623 — 5,121,069 74.90 
Stock options exercisable as of December 31, 20247,578,056 58.376.40401 
(1) As of December 31, 2024 14,340 of the outstanding stock options were granted under the Company's Fourth Amended and Restated Stock Option Plan ("Legacy Option Plan") and are exercisable for Class B restricted voting shares, 14,535,048 of the outstanding stock options were granted under the Company's SOP and are exercisable for Class A subordinate voting shares, and 87,604 of the outstanding stock options were granted under the Deliverr 2017 Stock Option and Grant Plan and are exercisable for Class A subordinate voting shares.
(2) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of the Company's Class A subordinate voting shares as of December 31, 2024 and December 31, 2023.
Schedule of Assumptions Used to Estimate the Fair Value of Stock Options
The grant weighted average assumptions used to estimate the fair value of stock options granted to employees were as follows:    
Years ended
December 31, 2024December 31, 2023
Expected volatility65.6 %68.0 %
Risk-free interest rate4.17 %4.39 %
Dividend yieldNilNil
Average expected term3.93.8
Schedule of Classification of Stock-based Compensation
The following table illustrates the classification of stock-based compensation in the consolidated statement of operations and comprehensive income (loss), which includes both stock-based compensation and restricted share-based compensation expense:    
Years ended
December 31, 2024December 31, 2023December 31, 2022
(in US $ millions)
Cost of revenues449
Sales and marketing(1)
475663
Research and development(1)
287481386
General and administrative927491
430615549
(1) Includes accelerated stock-based compensation of $5 million and $164 million in sales and marketing and research and development, respectively, during the year ended December 31, 2023